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Objective: 18F FDG‐PET is superior to other imaging techniques in revealing resid-
ual laryngeal cancer after radiotherapy. Unfortunately, its specificity is low, due to
FDG uptake in inflammation and in anaerobic conditions. PET imaging with the
amino acid‐based radiopharmaceutical C11‐methionine (MET) should be less influ-
enced by post‐radiation conditions. The aim of this study was to investigate the
potential of MET in diagnosing recurrent laryngeal cancer after radiotherapy as com-
pared to 18F‐FDG.
Methods: Forty‐eight patients with a clinical suspicion of local residual disease at
least 3 months after completion of radiotherapy or chemoradiotherapy for a T2‐4
laryngeal carcinoma, along with an indication for direct laryngoscopy, were included.
They received MET‐PET and FDG‐PET prior to the direct laryngoscopy. One senior
nuclear medicine physician assessed both the FDG‐PET and MET‐PET images visu-
ally for the degree of abnormal uptake. The gold standard was a biopsy‐proven
recurrence 12 months after PET. The nuclear physician had no access to the medical
charts and was blinded to the results of the other PET. Sensitivity, specificity and
positive and negative predictive value were calculated.
Results: The sensitivity of FDG was 77.3% and the specificity 56.0% after the con-
servative reading, with these values equalling 54.5% and 76.0% for MET. The posi-
tive predictive value of FDG was 60.7% and the negative predictive value 73.7%.
The PPV of MET was 66.7%, and the NPV was 65.5%. The McNemar test within
diseased (sensitivity comparison) shows a p‐value of 0.125, and the McNemar test
within non‐diseased (specificity comparison) shows a P‐value of 0.180.
Conclusion: MET‐PET is not superior to FDG‐PET in terms of identifying recurrent
laryngeal cancer.
1 | INTRODUCTION
In the Netherlands, more than 80% of laryngeal cancers are primarily
irradiated. Salvage surgery is performed in case of residual disease,
but detection of residual or recurrent disease can be difficult after
radiotherapy. In the first half year after radiotherapy, residual or
recurrent disease especially can have a scattered and sub‐mucosal
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growth pattern, embedded in oedema and inflammatory tissue
(Figure 1).1 In some patients, these features will persist over the
ensuing years.
A positive biopsy, by means of endoscopy, is the gold standard
for confirming residual or recurrent disease, but a negative biopsy
does not necessarily exclude residual or recurrent disease. Several
direct laryngoscopies may be necessary to prove the presence of
residual or recurrent disease.2–4 In addition, the tissue damage
caused by biopsies may exacerbate the already existing inflamma-
tion, oedema and fibrosis.5 Conventional imaging techniques to
detect recurrent laryngeal carcinoma after radiotherapy include CT
and MRI. The sensitivity of both imaging techniques ranges from
58% to 72%.6,7 In clinical practice, these figures may indicate that
one needs to perform a direct laryngoscopy, despite negative CT or
MRI findings. FDG‐PET appeared to be helpful for select patients
with clinical suspicion of recurrent laryngeal carcinoma after radio-
therapy, when direct laryngoscopies under general anaesthesia with
biopsies were indicated.8 A systematic review by Brouwer and col-
leagues shows that FDG‐PET can help to reveal residual disease
after radiotherapy, with a sensitivity of 89% and a specificity of
74%.3 An explanation for the relatively low specificity could be the
uptake of FDG in activated macrophages. As in tumour cells, acti-
vated macrophages have an abundance of GLUT‐1 receptors and will
therefore have a high uptake of FDG.9,10 The conditions after radio-
therapy are characterised by non‐vital tumour cells and macrophages
dominating the former tumour site, regardless of the presence of
residual disease or not.11
The uptake of amino acids—methionine, for example—is high in
tumour cells but low in inflammatory tissues and could therefore be
a good alternative to FDG.12 C‐11 MET is an established radiophar-
maceutical and has been widely used to visualise intracranial
lesions.13 Methionine (MET) has also been successfully used in visu-
alising primary head and neck cancer.14–18 In addition to preclinical
studies validating MET in the evaluation of radiotherapy/chemoradio-
therapy, preclinical studies also showed a fast decline for MET in the
post‐radiation phase.19,20 Autoradiography shows that MET uptake
is predominantly located in viable tumour cells, with low uptake in
macrophages and nonviable tumour cells.21
In this study, we hypothesise that MET‐PET is better than FDG‐
PET in detecting recurrent disease in patients with clinical suspicion
of recurrent laryngeal carcinoma after radiotherapy.
2 | METHODS
2.1 | Patients
The protocol was approved by the ethics committee as required in
the Netherlands under the Medical Research Involving Human Sub-
jects Act. All patients provided written informed consent. Two uni-
versity hospitals recruited patients for the study.
Forty‐eight patients with a clinical suspicion—although no obvi-
ous local residual, recurrent disease or second primary at least
3 months after completing radiotherapy/chemoradiotherapy with
curative intent for a resectable T2‐4 laryngeal squamous cell carci-
noma—who had a clinical indication for direct laryngoscopy and
biopsy under general anaesthesia were included. Suspicion of recur-
rent disease was raised by the patient's complaints and changes on
physical examination that included fibre‐optic laryngoscopy. Exclu-
sion criteria were no younger than 18 years, a clinically evident
recurrence, and pregnancy. One patient had to be excluded because
parts of the PET scan registration were lost. The patient received
MET‐PET and FDG‐PET prior to direct laryngoscopy. The maximum
allowed timeframe between scans and laryngoscopy was 1 month.
2.2 | Ethical considerations
The protocol was approved by the ethics committee as required in
the Netherlands under the Medical Research Involving Human Sub-
jects Act. All patients provided written informed consent. Two uni-
versity hospitals recruited patients for the study.
2.2.1 | Procedures
C11‐methionine was prepared in our laboratory by 11C ‐methylation
of L‐homocysteine thiolactone using a Zymark robotic system. To
this end, a solution of L‐homocysteine thiolactone in a NaOH/etha-
nol mixture was put into a C18 cartridge followed by the passage of
C11‐methyl iodide. When the radioactivity on the cartridge was
maximal, C11‐methionine was eluted with a phosphate buffer
through a second C18 cartridge and a sterile filter to a sterile vial
containing saline. This end product was ready for injection and met
the following radiopharmaceutical criteria—radiochemical purity >
95%, specific activity > 10 000 GBq/mmol, sterile and pyrogen free,
pH 4.5‐8.5, ethanol <3.5%, D/L ratio >90%, osmolarity 200‐
800 mosmol/kg. We achieved successful C11‐methionine production
in>95% of syntheses.
F IGURE 1 Direct laryngoscopy patient 26. Originally T1N2aM0
supraglottic laryngeal cancer treatment 70 Gy radiotherapy. Clinical
suspicion recurrent disease due to deterioration quality of voice 2 y
after finishing radiotherapy. The second biopsy showed squamous
cell carcinoma
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F18‐FDG was produced according to the method of Hamacher
and colleagues, using an automated synthesis module.14 The radio-
chemical yield was 65.9% ± 7.1% (decay corrected).
The patients were scheduled for separate C11‐MET‐PET only
and F18‐FDGPET only scans, shortly before the direct laryngoscopy.
For both scans, patients were instructed to fast for at least 6 hours.
A5 MBq/kg C11‐MET or 5 MBq/kg F18‐FDG was injected intra-
venously and again after 20 or 60 minutes (for C11‐MET or F18‐
FDG, respectively). The scanning was performed on an ECAT EXACT
HR +PET camera (Siemens/CTI Inc) at both institutions, according to
the Netherlands protocol for standardisation and quantification of
FDG whole body PET studies in multi‐centre trials.22 The scanned
trajectory included skull base to the pelvis (Figures 1 and 2). PET
images were iteratively reconstructed (ordered subset expectation
maximisation). Both MET‐PET and FDG‐PET images were analysed
visually on a Leonardo workstation (Syngo Leonardo, Siemens AG,
Berlin).
Assessment of the PET images was performed visually for both
FDG‐PET and MET‐PET by one senior nuclear medicine physician
two years after inclusion was finished. He had no access to the med-
ical charts and was blinded to the result of the paired scan. First all
methionine PET images were assessed and in other session the FDG
images. The larynx was assessed by the degree of abnormal uptake
and side, and summarised in a three‐point scale: negative, equivocal
or positive for local recurrent disease. The PET report also included
information on lymph node involvement and distant metastases in
the field of view.
All but two patients underwent direct laryngoscopy under gen-
eral anaesthesia, combined with biopsies when indicated during
laryngoscopy at the discretion of the attending head and neck sur-
geon (Figure 3). After a negative direct laryngoscopy, the procedure
was repeated within two weeks if there was still a suspicion of
residual disease. If not, the head and neck surgeon evaluated the
patient every eight weeks, for a minimum period of 24 months. Two
patients did not undergo a direct laryngoscopy because of the com-
bination of poor general condition and a low level of suspicion.
These two patients did not develop residual disease within
24 months after PET scanning.
Outpatient clinic visits, hospital admission, operative procedures,
additional imaging and histological recurrence of tumour, the results
of any surgical procedure, and death were documented during the
follow‐up period.
Data were collected by the first author, and he was responsible
for the completeness and accuracy of the reported data and analy-
ses.
PET scans were evaluated both conservatively and sensitively.
Equivocal or positive was considered positive, and negative as nega-
tive, when evaluating the test characteristics sensitively. Positive
was considered positive, and negative and equivocal as negative,
when evaluating the test characteristics conservatively. In an attempt
to reduce false‐positive findings, MET‐PET scans were also sensi-
tively evaluated after excluding negative sensitive evaluated FDG‐
PET registrations. Histologically proven squamous cell carcinoma of
the larynx within 12 months after the MET‐PET registration was
considered the positive gold standard.
Sensitivity, specificity, positive and negative predictive value and
corresponding exact binomial 95% CIs were calculated using STATA
(StataCorp. 2015. Stata Statistical Software: Release 14.0, College Sta-
tion, TX: StataCorp LP.).
This study was powered to detect a difference of 10% in the
paired proportion of the sensitivity/specificity of FDG‐PET and MET‐
PET using the McNemar chi‐square test (power 80%; significance
level <0.05). For this purpose, 48 patients had to be included.F IGURE 2 Positive FDG-PET patient 26
F IGURE 3 Equivocal MET PET patient 26
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3 | RESULTS
Between November 1, 2008, and November 1, 2012, 48 patients
were included, one of whom had to be excluded due to loss of PET
data, which left 47 patients for analysis. Thirty‐eight of the patients
were male and nine female. The average age was 61 years with a
standard deviation of 6.7 years. Twenty patients had glottic, 24
supraglottic and 3 transglottic carcinoma. Twenty‐seven patients had
T2, 17 patients T3 and 3 patients T4 primary tumours before pri-
mary radiotherapy. Initially, ten patients had positive lymph nodes,
while none of the patients had distant metastases. Three patients
received chemoradiation and the other 44 radiation therapy only.
Details are listed in Table 1.
Thirty patients experienced a deterioration of their voice, 16 in
their swallowing function, 12 had a loss of weight and 24 experi-
enced an increase in pain. In 22 patients, the suspicion of a recur-
rence was moderate and in 25 patients severe, although not evident,
as assessed by their treating physician. The median time from com-
pletion of radiotherapy to the MET‐PET was 14 months, with a mini-
mum of 3 months, and a maximum of 13 years and 3 months. In 29
direct laryngoscopies, a biopsy was taken. Four patients underwent
more than one direct laryngoscopy; only in one patient were all (re-
peated) biopsies negative. Two residual cancers were not revealed
by either FDG‐PET or MET‐PET, and one was revealed by FDG‐PET
and not by MET‐PET. One residual disease was discovered after
three consecutive direct laryngoscopies with biopsy taken, and the
other two after two consecutive direct laryngoscopies. After
12 months, a total of 25 (53%) patients had not developed recurrent
disease, and after 24 months 20 patients. Ten patients died of the
disease, while six patients died of other causes. However, of the
patients who died of other causes, two patients were already known
to have incurable residual disease. Fourteen patients received a
laryngectomy. Six of the patients died of the disease after laryngec-
tomy. The remaining eight patients who received a laryngectomy
were still alive without evidence of disease 24 months after inclu-
sion.
The ten patients with initially positive lymph nodes did worse,
only three of them are still alive without disease. In four patients,
the FDG‐PET and MET‐PET showed distant metastases. In three
patients, the metastases were located in the lung, and in one patient,
bone metastases were visible. Although visible on both PET scans,
the FDG‐PET signal was clearer.
Using a conservative reading, the sensitivity of FDG‐PET was
77.3% (95% CI = 54.6‐92.2) and the specificity 56.0% (95% CI =
34.9‐75.6). The sensitivity of MET‐PET was 54.5 (95% CI = 32.2‐
75.6) and the specificity 76.0% (95% CI = 54.9‐90.6). FDG showed a
positive predictive value of 60.7% and a negative predictive value of
73.7%. The positive predictive value of MET was 66.7% and the
negative predictive value 65.5%. The McNemar test within diseased
(sensitivity comparison) shows a P‐value of 0.125, and the McNemar
test within non‐diseased (specificity comparison) shows a P‐value of
0.180.
Using the sensitive approach, the sensitivity of FDG‐PET was
95.5% (95% CI = 77.2‐99.9) and the specificity 24.0% (95% CI = 9.4‐
45.1). The sensitivity of MET‐PET was 86.4% (95% CI = 65.1‐97.1)
and the specificity 32.0% (95% CI = 14.9‐53.5). FDG showed a posi-
tive predictive value of 52.5% and a negative predictive value of
85.7%. The positive predictive value of MET was 52.8%, and the
negative predictive value was 72.7%. The McNemar test within dis-
eased (sensitivity comparison) shows a P‐value of 0.500, and the
McNemar test within non‐diseased (specificity comparison) shows a
P‐value of 0.625 (Table 2) .
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TABLE 2 The number positive, equivocal and negative PET
registrations after one year
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The combined approach using the FDG‐PET followed by the sen-
sitive MET‐PET, only if the FDG‐PET was positive or equivocal
(N = 40), led to a conversion of positive/equivocal evaluation to a
negative evaluation five times. Three of these five were negative
upon biopsy and therefore correctly classified as negative, while two
were positive upon direct biopsy, so these would have been missed
using this approach as compared to using FDG‐PET alone. The addi-
tion of MET‐PET therefore reduces the sensitivity, while only slightly
reducing the number of unnecessary biopsies. Values for the test
characteristics of this combined approach equalled: 86.4% sensitivity
(95% CI: 65.1‐97.1), 36% specificity (95% CI: 18.0‐57.5), 54.3% PPV
(95% CI: 36.8‐71.2) and 75% NPV (95%CI: 42.8‐94.5).
The patient who was included more than five years after finish-
ing radiotherapy had a false‐positive FDG and MET‐PET.
Seventeen patients were included between 1 and 5 years after
finishing radiotherapy. Using the conservative reading, the sensitivity
of FDG‐PET was 80.0% (95% CI = 0.6‐1.0.), the specificity 60.1%
(95% CI = 0.09‐1.00), the PPV 65.6% and the NPV 78.1%. Twenty‐
six patients were included between three and twelve months after
finishing radiotherapy. Using the conservative reading, the sensitivity
of FDG‐PET was 75.3% (95% CI = 0.61‐0.89), the specificity 53.3%
(95% CI = 0.05‐1.00), the PPV 61.5% and the NPV 73.2%.
Using the conservative reading, the sensitivity of MET‐PET in
the group of patients who were included between 1 and 5 years
was 57.4% (95% CI = 0.37‐0.77), the specificity 80.4% (95% CI =
0.32‐1.00), the PPV 70.80% and the NPV 69.30%.
The sensitivity in the group of patients who were included
between three and twelve months after finishing radiotherapy was
52.8% (95% CI = 0.21‐0.83), the specificity 76.0% (95% CI = 0.36‐
1.00), the PPV 65.4% and the NPV 63.3%.
4 | DISCUSSION
Because the majority of recurrent laryngeal cancers after radiother-
apy can be salvaged if detected in a timely fashion, early detection
of recurrent disease is of importance.23 However, it may be difficult
to differentiate between recurrence and post‐radiation changes.5 In
the present study, FDG‐PET was able to detect recurrent laryngeal
cancer after radiotherapy, with results worse than those results
obtained in other studies.6,8,24,25 This can be explained by the selec-
tion of our population. In most of the studies, patients with obvious
residual/recurrent disease were included, while we excluded these
patients.
Three recurrent diseases were not demonstrated by PET after the
conservative reading: two were not demonstrated by MET‐PET, and
one not by either FDG‐PET or MET‐PET. These recurrent diseases
were also not diagnosed by a direct laryngoscopy with taking of biop-
sies. Two or more direct laryngoscopies were necessary to diagnose
the residual cancer. This shows that a false‐negative PET had no
more influence on the time of laryngectomy than a traditional
workup. These findings are in agreement with the literature.5,26
In addition to reliable detection of residual or recurrent laryngeal
carcinoma after radiotherapy, PET is able to detect distant
metastases.27–29 Although the metastases were revealed both by
FDG and MET‐PET, they were more clearly visualised by FDG‐PET.
FDG‐PET is our preference for detecting distant metastases.
To make a reliable selection for direct laryngoscopy, a combina-
tion of high sensitivity and high negative predictive value is manda-
tory. The sensitive reading of the FDG results meets these demands.
Unfortunately, the positive predictive value is much lower. This
could result in a considerable number of unnecessary direct laryngo-
scopies, if PET were used to select patients for this procedure.
To avoid unnecessary direct laryngoscopies under general anaes-
thesia, a higher positive predictive value is needed. The search for
an alternative to FDG was mainly driven by a desire to improve the
positive predictive value. The main goal of this study—an improve-
ment in the positive predictive value without reducing the negative
predictive value—was not achieved. The positive predictive value of
MET for the conservative reading was slightly higher, although not
significant, than the positive predictive value obtained with FDG.
The negative predictive of 65.5% was too low, which implies that
MET‐PET cannot be used to select patients for a direct laryn-
goscopy.
It would be interesting to know whether MET‐PET is able to dis-
tinguish false‐positive FDG‐PET scans from true‐positive FDG‐PET
scans. The combined approach using sensitive MET‐PET only for
FDG‐PET positive/equivocal scans shows that the number of unnec-
essary biopsies is slightly reduced at the cost of missing positive
cases. These findings show that MET selects better, although not
well enough to reduce the number of unnecessary direct laryngo-
scopies significantly and safely.
We have no explanation for these disappointing results. It is
known that recurrent disease after radiotherapy is usually scattered
and embedded in inflammatory tissue. This is why we conducted this
pilot study. This small study did show that even early laryngeal can-
cers (T1‐2 glottic) were excellently visualised with MET.14 Since the
major part of this study was carried out using an older generation
PET camera, one would expect that the results in this study might
have been better due to the improved sensitivity of the new genera-
tion of PET cameras. The limited size of recurrent disease found
should therefore not be an important reason for the low sensitivity
observed.
In contrast to FDG, MET visualises more than a single pathway.
MET has a considerable non‐protein synthesis part, which makes
MET unsuitable for quantitative analyses.12 However, the non‐
protein synthesis pathways are more strongly activated by malig-
nancies than inflammation. The negative effects of non‐protein
pathways on the visualisation of recurrent disease should therefore
be limited. Although high salivary gland activity is demonstrated by
MET‐PET, it is unlikely that this hampered interpretation of PET,
because the larynx is out of the field of the submandibular and
parotid glands.
A more likely explanation could be the tumour‐to‐background
ratio. The tumour‐to‐background ratio of FDG is higher than the
ratio obtained with MET.12 Although the uptake of FDG in inflam-
matory tissues is thought to be higher than the uptake of MET,
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recurrent disease is probably better detected due to the absolutely
stronger uptake of FDG in a malignancy (Figures 2 and 3.).
Most malignancies show, in addition to an increased glucose
metabolism, an increased metabolism of amino acids, nucleosides
and phospholipids. Parts of malignancies may be hypoxic and may
have molecular targets on their cells.
Several amino acids, the nucleoside thymidine, the precursor for
the biosynthesis of phospholipids choline, hypoxia tracers and labelled
monoclonal antibodies are incorporated in radiopharmaceuticals,
which could be alternatives to FDG. The literature shows only a few
studies in which an alternative to FDG is used to visualise recurrent
head and neck carcinoma after radiotherapy. These studies have their
limitations because none of the studies include more than 20 patients,
and they frequently deal with more than one sub‐site. These studies
show that 11C‐choline and FLT visualise primary and recurrent head
and neck cancer slightly worse than FDG does.28–31 The amino acid
tyrosine (TYR) and O‐(2‐[18F] fluor ethyl)‐L‐tyrosine (FET) are the only
radiopharmaceuticals that show results that are equal or better than
those obtained with FDG for visualising recurrent or residual head and
neck carcinomas. Unfortunately the laborious production processes
are a serious limitation to using TYR and FET on a larger scale.32–34
To answer the question of whether other radiopharmaceuticals
are more suitable for revealing recurrent laryngeal disease after
radiotherapy, studies designed like ours need to be conducted.
5 | CONCLUSION
MET‐PET is not superior to FDG‐PET for identifying recurrent laryn-
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